Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/03/2005WO2005018486A2 Use of melatonin-containing oral supplement with animals
03/03/2005WO2005018330A1 Dosing regimen for flaviviridae therapy
03/03/2005WO2005018316A1 Hypertrophic cardiomyopathy model animal
03/03/2005WO2005009420A3 Pharmaceutical compositions of short-acting sedative hypnotic agent
03/03/2005WO2005009124A3 Environmentally safe fungicides
03/03/2005WO2005007142A3 Liquid compositions comprising formoterol
03/03/2005WO2005007070A3 Stable pharmaceutical composition
03/03/2005WO2005003085A3 Tajixanthone hydrate and tajixanthone hydrate derivatives, biological activities thereof, and use thereof
03/03/2005WO2005000309A3 Chemical compounds
03/03/2005WO2005000285A3 METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
03/03/2005WO2004113274A3 Diaryl ureas with kinase inhibiting activity
03/03/2005WO2004112761A3 Stable 5, 10-methylene-tetrahydrofolate pharmaceutical compounds
03/03/2005WO2004110350A3 Compouds and uses thereof in modulating amyloid beta
03/03/2005WO2004110151A8 Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
03/03/2005WO2004105766A3 Use of lornoxicam or lornoxicam analogue compounds
03/03/2005WO2004105738A3 Use of tetrahydropyridine derivatives
03/03/2005WO2004105695A3 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer’s disease
03/03/2005WO2004103309A3 Immunosuppressant compounds and compositions
03/03/2005WO2004103306A3 Immunosuppressant compounds and compositions
03/03/2005WO2004103300A3 Compositions and methods of treating reduced blood flow to the cns with cox-2 inhibitors and cholinergic agents
03/03/2005WO2004103274A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
03/03/2005WO2004100525A3 System and method for blocking television signal having multiple different content ratings
03/03/2005WO2004098570B1 Nanoparticulate bioactive agents
03/03/2005WO2004098565A3 Implantable controlled release bioactive agent delivery device
03/03/2005WO2004096189A3 The dispersible alendronate microparticle formulation
03/03/2005WO2004094370A3 Antibacterial pyrazole carboxylic acid hydrazides
03/03/2005WO2004093812A3 Compounds that induce neuronal differentiation in embryonic stem cells
03/03/2005WO2004092404A3 Inhibitors of acidic mammalian chitinase as asthma therapeutics
03/03/2005WO2004091536A3 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
03/03/2005WO2004091530A3 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
03/03/2005WO2004091521A3 Methods and compositions for administration of trpv1 agonists
03/03/2005WO2004087701A8 Cyclic benzimidazoles
03/03/2005WO2004087100A3 Cladribine formulations for improved oral and transmucosal delivery
03/03/2005WO2004084801A3 Treatments for leishmaniasis
03/03/2005WO2004083235A3 Tie-2 modulators and methods of use
03/03/2005WO2004083173A3 Ketopiperazine derivatives as bradykinin antagonists
03/03/2005WO2004082606A8 Fused pyrrole compounds
03/03/2005WO2004078925A8 Methods and compositions for treating and preventing neurodegenerative diseases
03/03/2005WO2004078920A3 Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (kca)
03/03/2005WO2004076410A3 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
03/03/2005WO2004073623A3 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
03/03/2005WO2004071383A3 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
03/03/2005WO2004066967A3 Method and kit for reducing the symptoms of peripheral vascular disease
03/03/2005WO2004060341A3 Increasing skin cell renewal with water-soluble vitamin e
03/03/2005WO2004058185A3 Antiangiogenesis by inhibiting protein kinase ck2 activity
03/03/2005WO2004054513A3 Methods and compositions for treating and preventing ear infections
03/03/2005WO2004050647A8 Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof
03/03/2005WO2004035004A3 Effervescent compositions comprising bisphosphonates and methods related thereto
03/03/2005WO2004028477A3 Methods for treatment and/or prevention of retinal disease
03/03/2005WO2004006936A8 Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
03/03/2005WO2004001058A3 Transcription factor modulating compounds and methods of use thereof
03/03/2005WO2003102151A3 Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
03/03/2005WO2003089418A8 Indane acetic acid derivatives and their use as pharmaceutical agents
03/03/2005WO2003080110A8 Topical pathogenic-tissue-destroying liquid
03/03/2005WO2003050102A8 Novel compounds for the treatment of cardiac arrhythmia, synthesis, and methods of use
03/03/2005WO2003045317A3 Therapeutic protein and treatments
03/03/2005WO2003031405A3 Methods for the synthesis of substituted purines
03/03/2005US20050050589 Soya cell strains with high isoflavone content
03/03/2005US20050049659 Articles for therapeutic paraffin treatment and methods of use
03/03/2005US20050049424 6-Hydroxy isoflavones derivatives and medicaments involving same
03/03/2005US20050049419 Heterocyclic inhibitors of MEK and methods of use thereof
03/03/2005US20050049413 Quinoline derivatives
03/03/2005US20050049408 That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits
03/03/2005US20050049314 Buffering; near neutral to slightly alkaline pH
03/03/2005US20050049312 N-(1-adamantyl)alkyl]alkano-amidines, guanidines or N'-nitroguanidines; non-competitive receptor antagonists for the NMDA receptor
03/03/2005US20050049311 Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
03/03/2005US20050049309 Regulation of HIF protein levels via deubiquitination pathway
03/03/2005US20050049308 Apolipoprotein D degradation inhibitor
03/03/2005US20050049307 Organic thiol metal-free stabilizers and plasticizers for halogen-containing polymers
03/03/2005US20050049306 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same
03/03/2005US20050049305 Preventing apoptosis of sensory hair cells in corti organ of fetuses during perinatal period by reducing ototoxic effects
03/03/2005US20050049303 Adamantane derivatives
03/03/2005US20050049301 Containing active ingredient and bactericide effective against at least 2 different kinds selected from escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and enterococcus hirae
03/03/2005US20050049300 Converting the carboxyl group of a thromboxane ligand to an amide or amine to obtain an ocular hypotensive agent; mimic the vasoconstrictor properties of thromboxane A2 and its endoperoxide precursors, without causing concomitant platelet aggregation; post-surgery and post laser treatment
03/03/2005US20050049299 Selective inhibitors of stat-3 activation and uses thereof
03/03/2005US20050049298 pH controlled aqueous solvent extraction from plant material of carboxylic acid form; salt formation and extraction into organic solvent; decarboxylation; filtration and/or chromatographic purification
03/03/2005US20050049295 Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
03/03/2005US20050049294 Methods of using [3.2.0] heterocyclic compounds and analogs thereof
03/03/2005US20050049293 Increasing effect of released acetylcholine on hepatic muscarinic receptors
03/03/2005US20050049292 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression
03/03/2005US20050049291 Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors
03/03/2005US20050049290 Benzimidazole derivatives and their use as gnrh antagonists
03/03/2005US20050049289 Lowering prolactin serum level; attention deficit hyperactivity disorder (ADHD)
03/03/2005US20050049287 Treating pain using selective antagonists of persistent sodium current
03/03/2005US20050049286 Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation
03/03/2005US20050049283 Compounds that inhibit factor xa activity
03/03/2005US20050049282 Process
03/03/2005US20050049281 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
03/03/2005US20050049279 Sustained release daily dosage form comprising D-threo methylphenidate; substantially free of L-threo and erythro optical isomers; minimizing side effects, increasing efficacy
03/03/2005US20050049278 Anticarcinogenic agents; synthesis
03/03/2005US20050049277 Histamine H3 receptor antagonists; such as 2-(4-(n-ethyl)anilinoethoxyphenyl)imidazo[1,2-a]pyridine
03/03/2005US20050049275 Preparing pure (S) form; reacting free base with levorotatory camphor sulfonic acid in dimethylformamide:toluene solvent then precipitating
03/03/2005US20050049273 Acridone derivatives as anti-herpesvirus agents
03/03/2005US20050049272 Gastrointestinal disorders; inhibiting gastric acid secretion; such as 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-(N,N-diethyl)carbamide
03/03/2005US20050049268 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
03/03/2005US20050049267 Pin1-modulating compounds and methods of use thereof
03/03/2005US20050049266 a 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H )-one derivative; Dopamine D2L receptor and serotonin 5-HT2 receptor antagonist; antipsychotic
03/03/2005US20050049265 Use of inhibitors of i$g(k)b kinease for the treatment of cancer
03/03/2005US20050049263 Purine analogs having hsp90-inhibiting activity
03/03/2005US20050049262 Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease
1 ... 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 4782 4783 4784 4785 4786 ... 7860